causal
FDA misunderstood psychedelic combination treatment framing
The FDA denied the Lykos/MAPS MDMA-assisted therapy petition partly due to legitimate adverse-event reporting issues and overt bias concerns, but also because the FDA, as a drug-approving body, was confused by the combination treatment framing that emphasized psychotherapy, which falls outside its remit, tripping up the application.
causalpending
Speaker
Robin Carhart-HarrisEvidence Quote
“i think the fda made some errors in terms of their misunderstanding of psychedelic medicine and and therapy ultimately they're a regulatory body that approve drugs drugs as medicines”
Created: 6/14/2026, 2:08:07 AM
Your notes
Loading notes...